Insulin peglispro

Drug Profile

Insulin peglispro

Alternative Names: Basal insulin peglispro; BIL; LY-2605541; Pegylated insulin lispro

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Mar 2016 Eli Lilly withdraws a phase III trial in Type-2 diabetes mellitus in India, Israel, South Africa and China (NCT02106364)
  • 04 Dec 2015 Discontinued - Phase-I for Type-1 diabetes mellitus (Combination therapy) in Germany (SC)
  • 04 Dec 2015 Discontinued - Phase-I for Type-1 diabetes mellitus in Austria and USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top